Seven Fleet Capital Management LP
CIK: 2092021
Holdings (85)
Q3 2026 13F, quarter ended Sep 30, 2026, filed Nov 16, 2026
- CGON
CG ONCOLOGY INC
$133.72M
1.89M sh26.13%+0.0% - TNGX
TANGO THERAPEUTICS INC
$55.71M
2.23M sh10.89%-30.8% - RVMD
REVOLUTION MEDICINES INC
$54.31M
264,588 sh10.61%+9.3% - PHVS
PHARVARIS N V
$22.21M
700,084 sh4.34%-9.6% - ENTX
ENTERA BIO LTD
$19.97M
6.86M sh3.90%+3486.4% - LQDA
LIQUIDIA CORPORATION
$18.04M
596,275 sh3.53%+132.4% - AVBP
ARRIVENT BIOPHARMA INC
$13.66M
451,173 sh2.67%+83.0% - ELVN
ENLIVEN THERAPEUTICS INC
$12.01M
261,957 sh2.35%-28.3% - AVTX
AVALO THERAPEUTICS INC
$11.84M
772,660 sh2.31%+0.3% - XNCR
XENCOR INC
$11.1M
444,937 sh2.17%+20.8% - ROIV
ROIVANT SCIENCES LTD
$10.62M
290,280 sh2.07%+31.9% - ABVX
ABIVAX SA
$9.83M
99,274 sh1.92%-10.8% - ASMB
ASSEMBLY BIOSCIENCES INC
$9.81M
417,441 sh1.92%-3.6% - MANE
VERADERMICS INC
$9.7M
80,000 sh1.90%+0.0% - PTGX
PROTAGONIST THERAPEUTICS INC
$6.43M
45,659 sh1.26%+0.6% - DMRA
DAMORA THERAPEUTICS INC
$6.14M
288,439 sh1.20%New - IPSC
CENTURY THERAPEUTICS INC
$6.08M
4.42M sh1.19%+1.7% - EPRX
EUPRAXIA PHARMACEUTICALS INC
$5.21M
572,267 sh1.02%-6.3% - AXSM
AXSOME THERAPEUTICS INC.
$4.44M
24,066 sh0.87%-16.5% - SGMT
SAGIMET BIOSCIENCES INC
$4.24M
429,113 sh0.83%+6.3% - ZNTL
ZENTALIS PHARMACEUTICALS INC
$4.17M
1.50M sh0.81%+373.6% - DFTX
DEFINIUM THERAPEUTICS INC
$4.14M
108,647 sh0.81%-26.9% - DNTH
DIANTHUS THERAPEUTICS INC
$4.09M
46,432 sh0.80%-28.3% - SLN
SILENCE THERAPEUTICS PLC
$3.83M
350,000 sh0.75%+482.3% - TARS
TARSUS PHARMACEUTICALS INC
$3.81M
48,530 sh0.75%-58.5% - IMUX
IMMUNIC INC
$3.66M
687,240 sh0.72%New - TSHA
TAYSHA GENE THERAPIES INC
$3.65M
750,000 sh0.71%-50.1% - CYTK
CYTOKINETICS INC
$3.54M
53,748 sh0.69%-54.5% - NERV
MINERVA NEUROSCIENCES INC
$3.35M
1.00M sh0.66%+0.0% - RLAY
RELAY THERAPEUTICS INC
$3.35M
185,733 sh0.66%+4.2% - ZLAB
ZAI LAB LTD
$3.12M
118,395 sh0.61%-13.0% - PRAX
PRAXIS PRECISION MEDICINES I
$3.05M
10,489 sh0.60%+39.1% - CTMX
CYTOMX THERAPEUTICS INC.
$2.95M
1.09M sh0.58%+0.0% - EDIT
EDITAS MEDICINE INC
$2.94M
1.92M sh0.58%+44.0% - SABS
SAB BIOTHERAPEUTICS INC
$2.39M
752,772 sh0.47%+2.3% - ASND
ASCENDIS PHARMA A/S
$2.15M
9,440 sh0.42%-20.5% - ANL
ADLAI NORTYE GROUP LTD
$1.86M
116,185 sh0.36%+2.6% - STRO
SUTRO BIOPHARMA INC
$1.61M
99,894 sh0.31%-37.2% - UTHR
UNITED THERAPEUTICS CORP DEL
$1.59M
2,940 sh0.31%New - IVA
INVENTIVA SA
$1.53M
414,341 sh0.30%+107.0% - HRMY
HARMONY BIOSCIENCES HLDGS IN
$1.49M
37,900 sh0.29%New - ANTX
AN2 THERAPEUTICS INC
$1.35M
254,309 sh0.26%+21.7% - CLDX
CELLDEX THERAPEUTICS INC NEW
$1.32M
40,868 sh0.26%-52.8% - SMMT
SUMMIT THERAPEUTICS INC
$1.3M
76,648 sh0.25%+4.6% - PCVX
VAXCYTE INC
$1.26M
22,066 sh0.25%-25.9% - TCGX
TCGX ACQUISITION CORP
$1.25M
100,000 sh0.24%New - CTNM
CONTINEUM THERAPEUTICS INC
$1.16M
86,654 sh0.23%+43.1% - BHVN
BIOHAVEN LTD
$1.08M
81,221 sh0.21%New - SYRE
SPYRE THERAPEUTICS INC
$1.03M
11,611 sh0.20%-12.7% - INM
INMED PHARMACEUTICALS INC
$1M
1.07M sh0.20%New
| Security | Shares | Value | Change | Weight | Period |
|---|---|---|---|---|---|
CGON CG ONCOLOGY INC | 1.89M | $133.72M | +0.0% | 26.13% | Q3 2026 |
TNGX TANGO THERAPEUTICS INC | 2.23M | $55.71M | -30.8% | 10.89% | Q3 2026 |
RVMD REVOLUTION MEDICINES INC | 264,588 | $54.31M | +9.3% | 10.61% | Q3 2026 |
PHVS PHARVARIS N V | 700,084 | $22.21M | -9.6% | 4.34% | Q3 2026 |
ENTX ENTERA BIO LTD | 6.86M | $19.97M | +3486.4% | 3.90% | Q3 2026 |
LQDA LIQUIDIA CORPORATION | 596,275 | $18.04M | +132.4% | 3.53% | Q3 2026 |
AVBP ARRIVENT BIOPHARMA INC | 451,173 | $13.66M | +83.0% | 2.67% | Q3 2026 |
ELVN ENLIVEN THERAPEUTICS INC | 261,957 | $12.01M | -28.3% | 2.35% | Q3 2026 |
AVTX AVALO THERAPEUTICS INC | 772,660 | $11.84M | +0.3% | 2.31% | Q3 2026 |
XNCR XENCOR INC | 444,937 | $11.1M | +20.8% | 2.17% | Q3 2026 |
ROIV ROIVANT SCIENCES LTD | 290,280 | $10.62M | +31.9% | 2.07% | Q3 2026 |
ABVX ABIVAX SA | 99,274 | $9.83M | -10.8% | 1.92% | Q3 2026 |
ASMB ASSEMBLY BIOSCIENCES INC | 417,441 | $9.81M | -3.6% | 1.92% | Q3 2026 |
MANE VERADERMICS INC | 80,000 | $9.7M | +0.0% | 1.90% | Q3 2026 |
PTGX PROTAGONIST THERAPEUTICS INC | 45,659 | $6.43M | +0.6% | 1.26% | Q3 2026 |
DMRA DAMORA THERAPEUTICS INC | 288,439 | $6.14M | New | 1.20% | Q3 2026 |
IPSC CENTURY THERAPEUTICS INC | 4.42M | $6.08M | +1.7% | 1.19% | Q3 2026 |
EPRX EUPRAXIA PHARMACEUTICALS INC | 572,267 | $5.21M | -6.3% | 1.02% | Q3 2026 |
AXSM AXSOME THERAPEUTICS INC. | 24,066 | $4.44M | -16.5% | 0.87% | Q3 2026 |
SGMT SAGIMET BIOSCIENCES INC | 429,113 | $4.24M | +6.3% | 0.83% | Q3 2026 |
ZNTL ZENTALIS PHARMACEUTICALS INC | 1.50M | $4.17M | +373.6% | 0.81% | Q3 2026 |
DFTX DEFINIUM THERAPEUTICS INC | 108,647 | $4.14M | -26.9% | 0.81% | Q3 2026 |
DNTH DIANTHUS THERAPEUTICS INC | 46,432 | $4.09M | -28.3% | 0.80% | Q3 2026 |
SLN SILENCE THERAPEUTICS PLC | 350,000 | $3.83M | +482.3% | 0.75% | Q3 2026 |
TARS TARSUS PHARMACEUTICALS INC | 48,530 | $3.81M | -58.5% | 0.75% | Q3 2026 |
IMUX IMMUNIC INC | 687,240 | $3.66M | New | 0.72% | Q3 2026 |
TSHA TAYSHA GENE THERAPIES INC | 750,000 | $3.65M | -50.1% | 0.71% | Q3 2026 |
CYTK CYTOKINETICS INC | 53,748 | $3.54M | -54.5% | 0.69% | Q3 2026 |
NERV MINERVA NEUROSCIENCES INC | 1.00M | $3.35M | +0.0% | 0.66% | Q3 2026 |
RLAY RELAY THERAPEUTICS INC | 185,733 | $3.35M | +4.2% | 0.66% | Q3 2026 |
ZLAB ZAI LAB LTD | 118,395 | $3.12M | -13.0% | 0.61% | Q3 2026 |
PRAX PRAXIS PRECISION MEDICINES I | 10,489 | $3.05M | +39.1% | 0.60% | Q3 2026 |
CTMX CYTOMX THERAPEUTICS INC. | 1.09M | $2.95M | +0.0% | 0.58% | Q3 2026 |
EDIT EDITAS MEDICINE INC | 1.92M | $2.94M | +44.0% | 0.58% | Q3 2026 |
SABS SAB BIOTHERAPEUTICS INC | 752,772 | $2.39M | +2.3% | 0.47% | Q3 2026 |
ASND ASCENDIS PHARMA A/S | 9,440 | $2.15M | -20.5% | 0.42% | Q3 2026 |
ANL ADLAI NORTYE GROUP LTD | 116,185 | $1.86M | +2.6% | 0.36% | Q3 2026 |
STRO SUTRO BIOPHARMA INC | 99,894 | $1.61M | -37.2% | 0.31% | Q3 2026 |
UTHR UNITED THERAPEUTICS CORP DEL | 2,940 | $1.59M | New | 0.31% | Q3 2026 |
IVA INVENTIVA SA | 414,341 | $1.53M | +107.0% | 0.30% | Q3 2026 |
HRMY HARMONY BIOSCIENCES HLDGS IN | 37,900 | $1.49M | New | 0.29% | Q3 2026 |
ANTX AN2 THERAPEUTICS INC | 254,309 | $1.35M | +21.7% | 0.26% | Q3 2026 |
CLDX CELLDEX THERAPEUTICS INC NEW | 40,868 | $1.32M | -52.8% | 0.26% | Q3 2026 |
SMMT SUMMIT THERAPEUTICS INC | 76,648 | $1.3M | +4.6% | 0.25% | Q3 2026 |
PCVX VAXCYTE INC | 22,066 | $1.26M | -25.9% | 0.25% | Q3 2026 |
TCGX TCGX ACQUISITION CORP | 100,000 | $1.25M | New | 0.24% | Q3 2026 |
CTNM CONTINEUM THERAPEUTICS INC | 86,654 | $1.16M | +43.1% | 0.23% | Q3 2026 |
BHVN BIOHAVEN LTD | 81,221 | $1.08M | New | 0.21% | Q3 2026 |
SYRE SPYRE THERAPEUTICS INC | 11,611 | $1.03M | -12.7% | 0.20% | Q3 2026 |
INM INMED PHARMACEUTICALS INC | 1.07M | $1M | New | 0.20% | Q3 2026 |
1-50 of 85 holdings
Sector Allocation
SEC Filings
| Form | Description | Filed |
|---|---|---|
Seven Fleet Capital Management LP filed its most recent 13F holdings report, covering Q3 2026 (the quarter ended Sep 30, 2026), on Nov 16, 2026. Its largest reported positions by value are CGON, TNGX, RVMD, PHVS and ENTX. A 13F lists US-listed stock and option positions, not total assets under management.
About Seven Fleet Capital Management LP
Seven Fleet Capital Management LP is an Investment Adviser that reports its US-listed stock and option positions to the SEC on Form 13F (CIK 2092021). Signal8 holds 12 13F filings from it. Its SEC filings list California as its state of incorporation.
Its most recent 13F holdings report covers Q3 2026 (the quarter ended Sep 30, 2026) and was filed on Nov 16, 2026. That report lists 85 securities, not counting options, down from 96 in Q2 2026.
Its five largest reported positions, in order, are CG ONCOLOGY INC (CGON), TANGO THERAPEUTICS INC (TNGX), REVOLUTION MEDICINES INC (RVMD), PHARVARIS N V (PHVS) and ENTERA BIO LTD (ENTX). The next five are LIQUIDIA CORPORATION (LQDA), ARRIVENT BIOPHARMA INC (AVBP), ENLIVEN THERAPEUTICS INC (ELVN), AVALO THERAPEUTICS INC (AVTX) and XENCOR INC (XNCR).
Recent 13F filings by Seven Fleet Capital Management LP
- Q3 2026: 13F-HR filed Nov 16, 2026, listing 85 securities.
- Q2 2026: 13F-HR filed Aug 14, 2026, listing 96 securities.
- Q1 2026: 13F-HR/A filed Jun 4, 2026, listing 115 securities.
- Q1 2026: 13F-HR filed May 15, 2026, listing 114 securities.
- Q4 2025: 13F-HR/A filed Apr 1, 2026, listing 85 securities.
- Q4 2025: 13F-HR filed Feb 26, 2026, listing 85 securities.